Frontotemporal Dementia (FTD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Frontotemporal dementia (FTD) is a range of neurodegenerative disorders characterized by diverse clinical manifestations and two main underlying neuropathological profiles. Within FTD, there are typically three distinct clinical syndromes: behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). Furthermore, FTD often exhibits clinical and neuropathological overlaps with three other neurodegenerative conditions: corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS). These syndromes can be associated with different underlying neuropathological diagnoses collectively termed frontotemporal lobar degeneration (FTLD). The most prevalent forms of FTD are as follows:

1.       Frontal variant: This type primarily impacts behavior and personality.

2.       Primary progressive aphasia: This category involves communication difficulties and has two subtypes:

·       Progressive nonfluent aphasia, which impairs speech abilities.

·       Semantic dementia, which hampers language comprehension and usage.

Up to 50% of FTD cases with autosomal-dominant inheritance have a family history of FTD. Clinical diagnoses include behavioral variant FTD (bvFTD), primary progressive aphasia (PPA) affecting language, and disorders primarily affecting movements, such as progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). The US FDA has not approved any drug to treat frontotemporal dementia.

·       The annual prevalence of FTD varies from 18 to 25 cases per 100,000 individuals in the USA. FTD ranks as the second most common form of dementia among people under 65, and its prevalence is expected to increase with the aging population.

 

Thelansis’s “Frontotemporal Dementia (FTD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Frontotemporal Dementia (FTD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Frontotemporal Dementia (FTD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Frontotemporal Dementia (FTD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Frontotemporal Dementia (FTD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Frontotemporal Dementia (FTD), Frontotemporal Dementia (FTD) market outlook, Frontotemporal Dementia (FTD) competitive landscape, Frontotemporal Dementia (FTD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)